According to a press release from the pharmaceutical company, the European Commission's approval covers the treatment of adult patients with operable, early, and locally advanced gastric cancer.
The approved treatment includes two cycles of Imfinzi in combination with chemotherapy before and after surgery, followed by doses of Imfinzi alone.
Stomach cancer is the fifth most common cause of cancer death globally, with nearly one million people diagnosed each year.
